Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Official Title

DREAMM 7: A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma

Summary:

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Trial Description

Primary Outcome:

  • Progression-free survival
Secondary Outcome:
  • Complete response rate (CRR)
  • Overall response rate (ORR)
  • Duration of response (DoR) after administration of study treatment
  • Time to response (TTR) after administration of study treatment
  • Time to Progression (TTP) after administration of study treatment
  • Overall survival (OS)
  • Progression-free survival on subsequent line of therapy (PFS2)
  • Minimal Residual Disease (MRD) negativity rate after administration of study treatment
  • Number of participants with adverse events (AEs)
  • Number of participants with serious adverse events (SAEs)
  • Number of participants with abnormal ocular findings on ophthalmic examination
  • Plasma concentrations of belantamab mafodotin at indicated time points
  • Plasma concentrations of total monoclonal antibody (mAb) at indicated time points
  • Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points
  • Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin
  • Titers of ADAs against belantamab mafodotin
  • Change from Baseline in symptoms as measured by Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
  • Change from Baseline in impacts as measured by PRO-CTCAE
  • Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30)
  • Change from Baseline in HRQoL as measured by EORTC, 20-Item Multiple Myeloma Module (QLQ-MY20)
Approximately 478 participants will be randomized 1:1 to Arm A (B-Vd) or Arm B (D-Vd). Treatment will continue in both arms until progressive disease, death, unacceptable toxicity, withdrawal of consent or end of study, whichever occurs first.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society